New Delhi, August 8, 2025: Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), reported strong Q1 FY26 results with healthy growth in profitability and a landmark regulatory achievement.
For the quarter ended June 30, 2025, Akums posted total income of ₹1,051 crore, with Adjusted EBITDA of ₹156 crore, reflecting 19.1% year-on-year growth. Margins improved to 14.8%, up from 12.7% last year. Adjusted PAT rose to ₹65 crore, representing a margin of 6.2%.
During the quarter, the company secured 27 new Drug Controller General of India (DCGI) approvals, taking its total to 1,000 approvals — a milestone that strengthens its differentiated, research-led product portfolio. Akums also received a patent for an extended-release combination of Doxylamine and Pyridoxine developed using its proprietary tablet-in-tablet technology.
International expansion continued, with the company obtaining its first EU dossier approval for Rivaroxaban and filing its first Dapagliflozin combination dossier in Switzerland. The commercialization of its EU contract remains on track for April 2027. Akums received €100 million as part consideration for the EU contract, resulting in a cash surplus of ₹1,518 crore at the end of Q1 FY26.
Segment Performance
- CDMO: Contributed ~79% of group turnover with an EBITDA margin of 14.7%.
- Domestic branded formulations: ~3% YoY growth.
- International branded formulations: ~2% YoY growth.
- Trade generics & API: Continued operational losses, but losses are narrowing.
Management Commentary
“This marks just over a year since our listing, and we remain focused on long-term growth and our goal of becoming a global CDMO leader,” said Sanjeev Jain, Managing Director.
“Despite industry headwinds, we’ve delivered robust performance backed by R&D strength. Crossing 1,000 DCGI approvals gives us a unique edge in offering differentiated, margin-accretive products,” added Sandeep Jain, Managing Director.
Key Financial Highlights (₹ crore)
| Particulars | Q1 FY26 | Q4 FY25 | Q1 FY25 |
|---|---|---|---|
| Revenue | 1,024 | 1,056 | 1,019 |
| Other Income | 27 | 18 | 7 |
| Total Income | 1,051 | 1,073 | 1,026 |
| Adj EBITDA | 156 | 111 | 131 |
| Adj EBITDA Margin | 14.8% | 10.4% | 12.7% |
| Adj PAT | 65 | 44 | 57 |
| Adj PAT Margin | 6.2% | 4.1% | 5.6% |
